Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SpectraCure P18 + Verteporfin in Localized Prostate Cancer
2024-519658-35-00Phase 2Authorised
- Sponsor
- SpectraCure
- Start
- May 2025
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of verteporfin in prostate cancer (PCa), sponsored by SpectraCure. Primary endpoint: Safety: toxicity and PDT-mediated damage. Planned start May 2025; status: authorised.
02
Drugs
verteporfin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2024-519658-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519658-35-00.